After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
MRNS belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Marinus Pharmaceuticals Inc is $78.68M. A total of 2.87 million shares were traded on the day, compared to an average of 1.70M shares.
In the most recent transaction, Shafer Christina sold 2,153 shares of MRNS for 9.56 per share on Feb 20 ’24. After the transaction, the CHIEF COMMERCIAL OFFICER now owns 60,308 company shares. In a previous transaction on Feb 20 ’24, MANNING MARTHA E sold 1,894 shares at 9.57 per share. MRNS shares that SVP, GEN. COUNSEL & CORP. SEC. owns now total 52,966.
Among the insiders who sold shares, Braunstein Scott disposed of 11,850 shares on Feb 16 ’24 at a per-share price of $9.94. This resulted in the CHAIRMAN AND CEO holding 223,512 shares of MRNS after the transaction. In another insider transaction, Pfanstiel Steven sold 3,092 shares at $9.97 per share on Feb 16 ’24. Company shares held by the CFO AND COO now total 71,697.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, MRNS has a high of $11.26 and a low of $1.11.
As of this writing, MRNS has an earnings estimate of -$0.66 per share for the current quarter. EPS was calculated based on a consensus of 11.0 estimates, with a high estimate of -$0.61 per share and a lower estimate of -$0.79. The company reported an EPS of -$0.67 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. MRNS’s latest balance sheet shows that the firm has $122.93M in Cash & Short Term Investments as of fiscal 2021. There were $43.34M in debt and $40.57M in liabilities at the time. Its Book Value Per Share was $0.31, while its Total Shareholder’s Equity was $53.49M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MRNS is Buy with a score of 4.45.
